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Abstract
Objective: Pre-pregnancy weight, nutritional status, and the amount of weight gained during pregnancy, are extremely
useful indicators of fetal growth and outcome. Suboptimal maternal nutrition could have a direct effect on the organs of the
developing fetus and/or affect the endocrine milieu in the maternal feto-placental unit resulting in “fetal growth restriction”
which may be a significant risk factor for adult onset disease. We investigated endocrine adaptation by the fetus to overcome
the growth disadvantage caused due to poor weight gain in pregnancy as a result of maternal nutritional restriction.
Materials and Methods: We examined the quantitative variations in hormonal profiles in paired maternal and cord blood
samples obtained from mothers and their neonates who were classified based on maternal weight gain during the entire
pregnancy.
Results: 1) A total of 37.4% mothers gained less than 6 kg during the entire pregnancy. 2) Anthropometric parameters
measured in the mothers indicate that these mothers were nutritionally restricted both prior to and during pregnancy. 3) We
observed increased levels of growth hormone, placental lactogen, prolactin and thyroxine (T4) and decreased levels of insulin
in the cord blood of neonates and decreased insulin and TSH levels in maternal blood in the study group (<6 kg weight
gain during pregnancy) as compared to the control group (>6 kg weight gain during pregnancy).
Discussion: Our results suggest that insufficient weight gain in pregnancy due to suboptimal maternal nutritional status
results in fetal adaptation to a growth restricted environment by modulation of the pituitary-thyroid axis thereby altering the
endocrine milieu resulting in significant “fetal growth restriction”.
Keywords: pre-pregnancy weight, weight gain during pregnancy, intrauterine growth restriction, low birth weight,
endocrine function, maternal malnutrition
Özet
Hamilelik Öncesi Kilo ve Hamilelikte Al›nan Kilo Fetal Büyüme K›s›tlanmas›n›n
Endokrin Modülasyonunda Önemli Belirleyicilerdir
Amaç: Hamilelik öncesi kilo, beslenme statüsü ve hamilelikte al›nan kilo fetal geliflme ve prognoz aç›s›ndan çok önemli gös-
tergelerdir. Suboptimal bir maternal beslenme, geliflmekte olan fetüsün organlar›na do¤rudan etki edebilir ve/veya fetal bü-
yüme k›s›tlanmas›na yol açabilecek maternal feto-plasental ünitedeki endokrin ortam› bozabilir. Bu da, yetiflkinlikte ortaya
ç›kan hastal›klar için önemli bir risk faktörü olabilir. Bu çal›flmada, maternal beslenme bozukluklar›n›n bir sonucu olarak
yetersiz kilo al›m›n›n neden oldu¤u fetal büyüme k›s›tl›l›¤›n›n üstesinden gelebilmek için fetüsün endokrin adaptasyonu
incelenmifltir.
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Introduction
A healthy body weight promotes general health, reduces the
risk of developing some diseases and is a major positive
influence on the management and outcome of pregnancy.
Pre-pregnancy weight and nutritional status, and the amount
of weight gained during pregnancy are extremely useful
indicators of fetal growth and outcome. Therapeutic inter-
ventions of these parameters potentially reduce the incidence
of low birth weight (LBW) and growth restricted infants (1).
The World Health Organisation (WHO) recommends that
women in developing countries gain at least 1 kg per month
during the last two trimesters of pregnancy, resulting in a
weight gain of at least 6 kg. Although attainable and realistic,
most women in developing countries still do not gain the
recommended amount of weight (2-6). Prepregnancy weight
and pregnancy weight gain are independent and completely
additive and/or subtractive in their effect on birth weight,
together accounting for a difference of up to 1000 grams in
birth weight (5). The height and weight of mothers from
developing countries like India are lower by almost two stan-
dard deviations as compared to mothers from the developed
countries. Additionally, birth weight and placental weight of
neonates are also significantly lower in neonates born to these
mothers. According to the most recent estimates, 15.5% of
all births, or more than 20 million infants worldwide, are
born with LBW. The incidence of LBW in developing
countries is 16.5% which is more than double in developed
nations. More than 95% of low birth weight babies are born
in developing countries, and this high prevalence of LBW
neonates is a major public health problem (7).
Fetal growth is also affected by endocrine parameters like hor-
mones and growth factors and genetic factors. Hormones and
growth factors of maternal and feto-placental origin
have been demonstrated to play an important role with the ac-
cretion and differentiation of fetal tissues. The peptide
hormones, insulin, prolactin, placental lactogen, growth
hormone and the growth factors, insulin like growth factor
(IGF-I, IGF-II) and epidermal growth factor (EGF), have
been shown to be of specific relevance in fetal growth and de-
velopment (8-10). Additionally, the thyroid hormones
stimulate protein synthesis and cell enlargement and are vital
for fetal maturation. Caloric deprivation resulting in maternal
malnutrition during this very critical period of development
disturbs maternal thyroid function and leads to an imbalance in
the fetal thyroid hormone profile, resulting in impairment of
brain development and function (8). “Barker’s hypothesis”
suggests that maternal malnutrition could have a direct effect
on the organs of the developing fetus and/or affect the endocrine
milieu which could modulate the delicate hormonal
balance in the maternal feto-placental unit resulting in Intra
Uterine Growth Retardation (IUGR) which may be a signifi-
cant risk factor for adult onset diseases (11-14). Maternal pre-
pregnancy weight represents long-term maternal nutritional
status and is responsible for approximately 13% of the variance
in birth weight. On the other hand, weight gain during preg-
nancy, represents short-term maternal nutritional status and
accounts for only 5.6% of the variance in birth weight (15-19).
Limited information is available in literature with regards to
the endocrine alterations in the maternal-fetal milieu as a
consequence of inadequate maternal weight gain during
pregnancy or nutritional restrictions in pregnancy. In order to
investigate the endocrine adaptation mechanisms by the fetus
to overcome the growth disadvantage caused by maternal
nutritional limitations, we examined the quantitative variations
in hormonal and growth factor profiles in paired maternal
and cord blood samples obtained from mothers and their
neonates who were classified into two study groups based on
the maternal weight gain in pregnancy.
Materials and Methods
Pregnant mothers (n=300) who were registered and being
followed up in the antenatal clinic in a prominent govern-
ment hospital in New Delhi, India and their newborns were
the source of the clinical material for this study. The study
design and the consent forms were approved by the appropri-
priate institutional review board and the study was conducted
strictly based on their recommended guidelines. After ob-
taining informed consent, a detailed clinical obstetric history
of the patient was documented. Gestational age was assessed
from the date of the last menstrual period. At birth, cord blood
(20 ml) was collected from the placental end into a sterile
heparinised tube and immediately centrifuged to separate the
plasma and aliquoted and stored at -20°C until further use.
The maternal blood drawn (10 ml) was also similarly collected,
aliquoted and stored until further analysis. Weight and length
of the neonate were recorded as soon as the baby was dried
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Materyal ve Metot: Gebelik boyunca maternal kilo al›m› temelinde grupland›r›lm›fl anne ve yenido¤anlardan al›nan mater-
nal ve kordon kan örneklerinin hormonal profillerindeki kantitatif de¤iflkenlikler incelenmifltir.
Sonuçlar: 1) Annelerin %37.4’ü gebelikleri boyunca 6 kg’dan az kilo alm›flt›r. 2) Annelerde ölçülen antropometrik paramet-
reler, bu annelerin gebelik öncesinde ve esnas›nda beslenme yetersizli¤ine maruz kald›klar›n› göstermektedir. 3) Kontrol
grubu ile karfl›laflt›rd›¤›m›zda (gebelik boyunca kilo al›m› >6 kg), çal›flma grubundaki (gebelik boyunca kilo al›m› <6 kg)
yenido¤anlar›n kordon kan›nda artm›fl seviyede büyüme hormonu, plasental laktojen, prolaktin ve tiroksin (T4) ve daha dü-
flük seviyede insülin, maternal kanda da daha düflük seviyede TSH saptanm›flt›r.
Tart›flma: Çal›flmam›z, suboptimal maternal beslenmenin yol açt›¤› yetersiz kilo al›m›n›n, hipofiz-tiroid aks›n›n modülasyonu
arac›l›¤›yla fetal büyümenin k›s›tlanmas› fleklinde yan›t oluflturmakta; bunun sonucu olarak da endokrin dengeler de¤iflerek
ciddi “fetal büyüme k›s›tlanmas›” ortaya ç›kmaktad›r.
Anahtar sözcükler: gebelik öncesi kilo, gebelik s›ras›nda kilo al›m›, intrauterin büyüme k›s›tlanmas›, düflük do¤um a¤›rl›¤›,
endokrin fonksiyon, maternal yetersiz beslenme
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and cleaned after delivery. Anthropometric data was ob-
tained from the mothers and the neonates. Maternal nutri-
tional status and fetal growth status was assessed using a
combination of anthropometric and biochemical parameters,
like body mass index (BMI) calculated from the height and
weight of the mother, mid arm circumference, abdominal
girth or abdominal circumference, fundal height. Maternal
weight gain during pregnancy and maternal pre-pregnancy
BMI were also measured. The biochemical parameters
measured to assess nutritional status were maternal and fetal
total protein and serum albumin levels. The methodology
used to measure total serum proteins was the standard Biuret
reaction in our routine clinical laboratory using an automated
sampler.
Anthropometric measures of the neonate
The following methodologies were used to measure birth
weight, length of the neonates (20-22).
Birth weight measurement: The pan-type pediatric scale was
used to measure birth weight of the neonate. The pan-type
pediatric scale is a beam scale with non-detachable weights
and is accurate within 10 grams. Birth weight was measured
in grams (g).
Length measurement: To measure neonatal length, an in-
house length-measuring device with a fixed headboard and a
moveable footboard that was perpendicular to the surface on
which the neonate was placed was used. A fixed measuring
tape was attached to the surface with the zero end at the
edge of the headboard. Length of the neonate was measured
in centimeters (cm).
Ponderal Index (PI): Ponderal index (PI)=birth weight/birth
length3 was calculated from the neonates weight and length
at birth.
Anthropometric measures of the mother
Abdominal circumference, fundal height, and mid arm
circumference were measured as published earlier (20-22).
Maternal pre-pregnancy weight: Pregnant mothers are
weighed during their first visit (6-8 weeks of pregnancy) to
the antenatal clinic.
Maternal weight at delivery: Pregnant mothers are weighed
when they are admitted into the labor room for delivery.
Women are weighed on a platform beam balance scale with
movable weights. Beam balances have the highest reliability
and validity and both maternal pre-pregnancy weight and
weight at delivery are expressed in kilograms (kg).
Weight gain during pregnancy: Weight gain during
pregnancy is expressed as the total weight gain during the
entire gestational period, up until the birth of the neonate. It
is expressed in kilograms and computed as follows; Weight
gain during pregnancy=weight at delivery subtracted from
the maternal pre-pregnancy weight.
Abdominal circumference: A simple circumference measure-
ment was taken at the mid-abdominal line using a non-
stretchable centimeter tape. Since fetal movements could result
in distortion of the abdominal shape, single measurements of
the abdominal circumference could be inaccurate, therefore
we took a minimum of three separate measurements of
abdominal circumference, and a mean value of all three
measurements was noted in centimeters (cm).
Mid-Arm Circumference (MAC): MAC is used as an indicator
for both screening acute adult under nutrition and for esti-
mating prevalence of under nutrition at a population level. To
measure MAC, we used a non-stretchable centimeter tape,
measurements were taken on the non-dominant arm bent at a
90˚ angle with palm facing up, the midpoint between the
acromium and olecranon processes was chosen as the measure-
ment mark point. The distance around the arm at this mark
point was recorded to the nearest 0.1 cm. Clothing was
pushed up above the shoulder or removed so that it did not
interfere with MAC measurement.
Fundal height: The fundal height is a rough estimate of fetal
size and is measured as the distance between the pubic bone
and uterine fundus. The fundal height measurement in centi-
meters (cm) was taken with a non-stretchable tape measure
from the top of the pubic bone to the fundus of the uterus.
Study design
The World Health Organisation (WHO) recommends that
women in developing countries gain at least 1 kg per month
during the last two trimesters of pregnancy, resulting in a
weight gain of at least 6 kg during the entire pregnancy.
Based on this recommendation, we classified the mothers in
the study into two groups Group I (Study group, weight gain
during pregnancy is <6 kg) and Group II (control group,
weight gain during pregnancy is ≥6 kg). Only term pregnancies
were included in the study, a gestational period of 38-42
weeks was considered normal and neonates born before 38
weeks were considered pre-term, while those beyond 42
weeks were considered post term. Exclusion criteria of the
study included both pre- and post term neonates and their
mothers and any other clinical disorders known to predispose
the mothers to LBW births excepting malnutrition and/or
anemia. Pregnant mothers with clinical disorders such as pre-
eclampsia, renovascular disease, chronic hypertension,
vasculopathy from diabetes, drug abuse, genetic or congenital
abnormalities, inborn errors of metabolism and toxic
exposure were excluded from the study.
To examine the endocrine profile of mothers and their neo-
nates in Group I and Group II, an array of hormones and
growth factors relevant to fetal growth and development, like
Growth Hormone (GH), PRoLactin (PRL), insulin, human
Placental Lactogen (hPL), thyroid hormones: (T4: thyroxine,
T3: tri-iodo-thyronine, rT3: reverse-tri-iodo-thyronine, TSH:
thyroid stimulating normone), Insulin- like Growth Factor-1
(IGF-1) and Epidermal Growth Factor (EGF) were assayed
in both cord blood and maternal blood using a combination
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of in-house radioimmunoassays and commercially available
kits. The standards, iodination material for preparation of the
radiolabelled antigen, and the specific antisera were obtained
from the National Hormone and Pituitary Program (NHPP)
of the National Institute of Arthritis, Diabetes and Digestive
and Kidney diseases (NIADDK), NIH, Bethesda, MD and the
assays were performed using a precise protocol provided by
this program. GH, PRL, hPL were assayed using the reagents
from NIH while Insulin, IGF-1, TSH and EGF were assayed
using a commercially available kits from Amersham Inc.
(Piscataway, NJ, USA). All the assays were highly specific
and sensitive with a intra and inter assay coefficient of
variation less than 10%. The minimum detectibility of the
GH, PRL, hPL, Insulin, IGF-1 and EGF assays was
0.23 ng/ml, 0.4 ng/ml, 0.015 mU/L, 0.4 mU/ml, 0.078 ng/ml
and 0.06 ng/ml, respectively. The minimum detectibility of the
T3, T4, rT3 and TSH assays was 2.5 pg/ml, 5 pg/ml, 1 pg/ml,
and 0.03 µU/ml, respectively.
Statistical analysis
Statistical analysis was done using ANOVA. Multiple com-
parisons between the study groups were performed using a
Bonferroni adjustment. The tables contain the p-values for
these pair wise group comparisons. All data analysis was done
using the normal control group as the reference group.
Additionally, multivariate regression analysis was done to
investigate relationships between weight gain and the
various anthropometric, biochemical and endocrine para-
meters. The statistical software used was Analyze-It (version
1.73) (Analyze It for Microsoft® Excel® Leeds, UK)
Results
A total of 300 cases were enrolled in the study. Only term
pregnancies with an uneventful perinatal period were included
in the study. The patient population was representative of the
majority of the urban and rural, low and middle socioecono-
mic class of the society. The mean gestational age of the
mothers was 39.13±1.03 weeks. Gestational age was assessed
from the date of the last menstrual period. The mothers in the
study were classified into two groups Group I consisting of
n=112 (study group, weight gain during pregnancy is <6 kg)
and Group II consisting of n=188 (control group, weight gain
during pregnancy is ≥6 kg). The mean age of the mothers in
the two groups was 20.7±1.8-years.
Anthropometric and biochemical measures of maternal
and fetal growth and nutritional status
Nutritional status of the mothers enrolled in the study was
assessed using both anthropometric and biochemical measure-
ments (Table 1). Our results show that maternal pre-preg-
nancy weight (kg) (46.01±4.61, p=0.0013) was significantly
lower in (Group I ) mothers who gained <6 kg weight during
pregnancy as compared to the normal control group of
mothers (47.76±5.32). Similar trend was observed with respect
to maternal weight at delivery, where maternal weight at
delivery (kg) (49.96±4.79, p=1.23E-13) was significantly
lower in Group I mothers as compared to the normal control
group of mothers (56.33±6.28). Maternal midarm circumfe-
rence (cm) (20.41±2.79, p=5.0E-06) in mothers from the
study Group I, was significantly lower as compared to the
normal control group of mothers (22.18±3.23). No signifi-
cant difference in maternal height was observed between the
two groups of mothers. These results indicate that maternal
pre-pregnancy nutritional status and pregnancy weight gain
also affect the survival and health of the newborn. Although
total weight gain during pregnancy is variable among women
with good pregnancy outcomes and because the perinatal
outcomes are multi-factorial in origin, weight gain is not a
perfect diagnostic criteria for fetal wellbeing, therefore ad-
ditional measures to assess fetal wellbeing such as maternal
abdominal circumference and maternal fundal height were
done. Our results show that maternal abdominal circumfe-
rence (cm), (84.30±5.46, p=0.000001) was significantly
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Maternal nutritional status Group I Group II (control)
(Weight gain <6 kg) (Weight gain ≥6 kg)
(n=112) (n=188)
Anthropometric parameters
Maternal pre-pregnancy weight (kg) 46.01±4.61 47.76±5.32 (p=0.0013)*
Maternal weight at delivery (kg) 49.96±4.79 56.33±6.28 (p=1.23E-13)*
Maternal height (cm) 154.9±4.78 154.70±4.73 (p=0.34, NS)
Maternal mid-arm circumference (cm) 20.41±2.79 22.18±3.23 (p=5E-06)*
Pre-pregnancy BMI (kg/m2) 19.19±2.07 19.97±2.19 (p=0.0011)
Weight gain during pregnancy (kg) 3.96±1.05 8.56±2.48 (p=2.9E-21)*
Maternal fundal height (cm) 29.99±2.67 30.95 ±3.21 (p=0.002)*
Maternal abdominal circumference (cm) 84.30±5.46 88.19±6.95 (p=0.000001)*
Biochemical parameters
Total protein (mg/dl) 7.13±0.92 7.02±1.26 (p=NS)
Serum albumin (mg/dl) 3.75±0.67 3.66±0.82 (p=NS)
Hemoglobin (g/L) 9.87±1.66 10.08±1.38 (p=NS)*
* denotes statistically significant differences between the study group and the control group
Table 1. Maternal anthropometric and biochemical parameters in the study groups
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lower in mothers in group I as compared to the normal
control group of mothers (88.19±6.95). Similar trend was
observed with respect to maternal fundal height (cm)
(29.99±2.67, p=0.002) which was significantly lower in the
study group as compared to the normal control group
(30.95±3.21).
Table 2 outlines the differences in fetal growth status
between the study group and the control group. Our results
showed significantly lower neonatal birth weight (g)
(2382.7±367.5, p=3.2E-20 ) in Group I, as compared to the
control group (Group II) (2886.6±348.9). Predictably, the
placental weight (g) was significantly lower (364.2±99.35,
p=3.4E-24) in Group I, as compared to the control group
(Group II) (449.5±110.91). Neonatal length (cm) was sig-
nificantly lower (49.03±2.17, p=0.0038) in Group I, as
compared to the control group (Group II) (49.69±1.85) and
consequently Ponderal Index (PI) which is a good measure
of asymmetrical fetal growth and computed from neonatal
birth weight and length, was also significantly lower
(2.02±0.30, p=0.0001) in Group I, as compared to the
control group (Group II) (2.35±0.28). The average birth
weight percentile (%) of neonates born to mothers who
gained <6 kg weight during the entire pregnancy was
26.8%, p=5.2E-25 as compared to the birth weight percen-
tile (58.6%) in neonates born to mothers who gained ≥6 kg
weight during the entire pregnancy. These results suggests
that a significant degree of fetal growth retardation is
evident in the neonates born to mothers who gained <6 kg
weight during the entire pregnancy, and its appears that is
fetal growth retardation is a consequence of not only
nutritional restriction during pregnancy but also due to poor
nutritional status prior to pregnancy as evident by a low
pre-pregnancy BMI. We measured the serum albumin and
total protein levels as a biochemical markers of nutritional
status in the maternal blood and cord blood in the two
48
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Fetal nutritional status Group I Group II (control)
(Weight gain <6 kg) (Weight gain ≥6 kg)
(n=112) (n=188)
Anthropometric parameters
Birth weight (gr) 2382.7±367.5 2886.6±348.9 (p=3.2E-20)*
Neonatal length (cm) 49.03±2.17 49.69±1.85 (p=0.0038)*
Ponderal index (cm) 2.02±0.30 2.35±0.28 (p=0.0001)*
Weight placenta (gr) 364.2±99.35 449.5±110.91 (p=3.4E-24)*
Birth weight percentile (%) 26.80±22.02 58.61±23.61(p=5.2E-25)*
Biochemical parameters
Total protein (mg/dl) 7.08±0.89 7.20±1.15 (p=0.16, NS)
Serum albumin (mg/dl) 3.92±0.64 4.11±0.79 (p=0.015)*
Hemoglobin (g/L) 12.52±1.98 12.90±1.26 (p=NS)
* denotes statistically significant differences between the study group and the control group
Table 2. Fetal anthropometric and biochemical parameters in the study groups
Cord blood Group I Group II (control)
(Weight gain <6 kg) (Weight gain ≥6 kg)
(n=112) (n=188)
Peptide hormones
Growth hormone (ng/ml) 38.57±25.13 33.88±20.51 (p=0.05)*
Prolactin (ng/ml) 301.8±58.1 276.17±28.9 (p=NS)
Insulin (mU/ml) 13.13±9.4 18.39±10.9 (p=0.016)*
Placental lactogen (mU/L) 82.98±15.2 55.25±11.0 (p=0.001)*
Growth factors
IGF-I (ng/ml) 223.5±98.3 237.5±123.2 (p=NS)*
EGF (ng/ml) 4.65±3.85 3.90±2.63 (p=NS)*
Thyroid hormones&Thyroid stimulating hormone
T4 (µg/dl) 8.75±3.33 8.04±3.01 (p=0.039)*
T3 (ng/dl) 44.06±20.52 53.06±25.48 (p=0.0007)*
rT3 (ng/dl) 208.44±95.65 225.1±100.85 (p=NS)
TSH (µU/ml) 4.85±3.42 5.27±4.07 (p=NS)
* denotes statistically significant differences between the study group and the control group
Table 3. Endocrine parameters measured in the cord blood
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study groups and the data indicates that there was no sig-
nificant difference in the maternal and cord blood total
protein levels in the two groups (Table 1, 2), however sig-
nificantly lower serum albumin (mg/dl) (3.92±0.64,
p=0.01) levels were observed in neonates who were born
to mothers who gained <6 kg weight during the entire
pregnancy, as compared to the respective normal controls
(4.11±0.79). Total hemoglobin levels were measured in
the maternal and cord blood as an index of hematological
status of the mothers and their neonates. No significant
differences in the hemoglobin levels were observed in the
paired maternal and cord samples in study group as
compared to the control group.
Endocrine parameters in cord blood in the two study groups
We measured the levels of the peptide hormones (GH, PRL,
insulin, HPL), growth factors (IGF-1 and EGF) and thyroid
hormones (T3, T4, rT3 and TSH) levels in the cord blood and
maternal blood in the two study groups (Table 3, 4). Data
(mean±SD) shows no statistically significant differences in
levels of Prolactin (PRL), the growth factors IGF-1 and EGF
or the thyroid hormones (rT3 and TSH) between the two
groups of neonates. However, a significant increase in GH
levels (ng/ml) (38.57±25.13, p<0.05) was observed in the
cord blood of neonates in Group I as compared to the cont-
rol group (33.88±20.51). Additionally, significantly higher
levels of cord blood HPL (mU/L) (82.98±15.2, p<0.001)
were observed in the neonates in Group I as compared to
Group II (55.25±11.0). However, the cord blood insulin
levels (mU/ml) were significantly lower in neonates in the
study group (13.13±9.4, p<0.016) as compared to the neo-
nates in the normal control group (18.39±10.09). As regards
the thyroid hormones cord blood T4 levels (µg/dl) were sig-
nificantly higher in the Group I neonates (8.75±3.33, p<0.03)
as compared to the neonates in the control group
(8.04±3.01), while an inverse trend was seen with respect to
T3 levels (ng/dl), where cord blood T3 levels were signifi-
cantly lower in the Group I neonates (44.06±20.52,
p<0.0007) as compared to the neonates in the control group
(53.06±25.48).
Endocrine parameters in maternal blood in the two
study groups
Data shown in Table 4 indicates no statistically significant
differences in maternal GH, HPL, PRL, IGF-1, EGF and
thyroid hormones (T3, T4, rT3) and TSH levels in mothers
who gained <6 kg weight during the entire pregnancy
(Group I) as compared to mothers who gained ≥6 kg weight
during the entire pregnancy Group II (control mothers). Sig-
nificant differences were observed in the Insulin levels
(mU/ml) which were significantly lower (43.92±19.1,
p<0.003) in Group I mothers as compared to Group II mothers
(74.010±17.7) and the TSH levels (µU/ml) were signifi-
cantly lower (1.72±1.03, p<0.02) in Group I mothers as
compared to the Group II mothers (2.18±1.5) (Table 4).
Table 5 outlines the results of our regression analysis and
Figure 1 shows the significant correlations between weight
gain in pregnancy in some of the key anthropometric and
endocrine parameters.
Discussion
Maternal nutritional status is a proximate determinant of
neonatal nutritional status. Maternal malnutrition could have
a direct effect on the organs of the developing fetus and/or
affect the endocrine milieu in the maternal feto-placental unit
resulting in IUGR which may be a significant risk factor for
adulthood diseases. In developing countries like India, majo-
rity of the LBW neonates are term but are IUGR (23). Fetal
growth is largely controlled by several variables such as
socio-economic factors, genetic factors and metabolic factors
that include the availability of oxygen and glucose and the
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Maternal blood Group I Group II (control)
(Weight gain <6 kg) (Weight gain ≥6 kg)
(n=112) (n=188)
Peptide hormones
Growth hormone (ng/ml) 14.531±12.4 13.61±12.83 (p=NS)
Prolactin (ng/ml) 363.7±316.2 449.7±275.3 (p=NS)
Insulin (mU/ml) 43.92±19.1 74.01±17.7 (p=0.003)*
Placental lactogen (mU/L) 2974.8±1250.3 3029.8±1647.6 (p=NS)
Growth factors
IGF-I (ng/ml) 125.2±28.2 141.3±53.61 (p=NS)
EGF (ng/ml) 8.2±3.5 8.08±2.44 (p=NS)
Thyroid hormones&Thyroid stimulating hormone
T4 (µg/dl) 10.071±3.18 9.71±3.13 (p=NS)
T3 (ng/dl) 122.4±42.8 121.1±38.9 (p=NS)
rT3 (ng/dl) 29.6±12.6 29.18±12.74 (p=NS)
TSH (µU/ml) 1.72±1.03 2.18±1.5 (p=0.02)
* denotes statistically significant differences between the study group and the control group
Table 4. Endocrine parameters measured in the maternal blood
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endocrine changes that results from the modulation of these
complex variables (24-26). In recent years, pioneering epide-
miological studies by Barker DJ et al. have opened up an
exciting new area of investigation that has focused on the
long-term adult consequences of fetal nutrient deprivation and
IUGR (11-14). Weight gained earlier in pregnancy primarily
contributes to maternal reserves, and is secondarily due to
the growth of the placenta, breasts, uterus and increased
amniotic and extra cellular fluids. After 20 weeks the fetus
begin to increase dramatically in size and many investigators
agree that weight gain in the second and third trimester is of
greater importance for ensuring fetal growth than weight
gain during the first trimester. LBW has long-term physiolo-
gical consequences, and a woman born as a LBW infant
herself may have difficulty developing a placenta that will
provide adequate nutrition to her own fetus (16,27).
All of the anthropometric parameters measured in the
mothers (except for maternal height) were indicative that the
mothers who gained less than 6 kg weight gain during the
entire pregnancy were nutritionally restricted both before
and during pregnancy. Data in Table 2 on the anthropometric
measurements of fetal growth indicated that neonates born to
mothers who gained less than 6 kg weight gain during the
entire pregnancy were growth restricted as indicated by sig-
nificantly lower birth weight, neonatal length, PI, placental
weight and birth weight percentile as compared to the control
group. Although we did not observe any change in total pro-
tein levels measured in the paired cord and maternal blood in
the two groups (Group I and Group II) of neonates and their
mothers, we observed a small but significant reduction in
serum albumin levels in the cord blood of neonates born to
Group I mothers. Serum albumin concentration is commonly
used as an index of nutritional status. During normal preg-
nancy, approximately 1000 g of weight gain is attributable to
protein, half of which is distributed in the fetus and the
placenta, while the remaining half is distributed as uterine
contractile protein, breast glandular tissue, plasma protein,
and hemoglobin. Decreased plasma albumin levels in the
cord blood of Group I neonates are indicative of limited
availability of nutrients for the growing fetus in these group
of mothers who gained less than 6 kg weight gain during the
entire pregnancy. The growth restriction of these neonates
was reflected in these significantly lower birth weight
percentile as compared to the control group of neonates who
were well above the 50% birth weight percentile. To deter-
mine the birth weight percentile the neonates were classified
based on the intrauterine growth curve validated by the
National Neonatology Forum of India and approved by the
Indian Council of Medical Research, and which was first
validated by Gopalan C, Singh M et al. followed by more up-
dated versions by Mohan M (15,23,28,29). These growth
curves are used as a standard for determining the adequacy
of weight gain of the fetus during gestation. Comparison
with western literature indicates a divergence or flattening of
the growth curve of Indian babies around 37 weeks of gestation
most likely reflecting the effect of maternal nutritional con-
straints. The growth curves used were adjusted for maternal
parity, fetal sex, socioeconomic status, and rural and urban
populations. Thus, these data suggest that poor maternal nut-
ritional status and consequently insufficient weight gain in
pregnancy were the primary cause of fetal growth restriction
in the neonates belonging to Group I.
The hormones and growth factors evaluated in the present
study are known to play an important roles in the tissue accre-
tion and differentiation in the fetus in several mammalian
species (30,31). The perinatal period presents a highly
synchronized sequence of metabolic and endocrine events
which are very important for normal growth and development
of the fetus (8-10,30,31). Significantly higher levels of pla-
cental lactogen and GH levels were observed in the cord blood
of neonates born to Group I mothers, while significantly lower
levels of cord blood insulin was observed in the same group.
We also observed a statistically significant increase in the
cord blood T4 levels and a significantly decrease in T3 levels
in Group I neonates (Table 3). Our maternal endocrine data
shows a significant decrease in insulin levels and TSH levels
in mothers who gained <6 kg weight during the pregnancy.
Human placental lactogen, which is synthesized and secreted
by the syncytiotrophoblast cells of the placenta, is a member
of the placental lactogen, growth hormone, prolactin gene
family. Several studies indicate a role for human placental
lactogen in the regulation of fetal growth, and its is speculated
that the growth-promoting actions of placental lactogen are
mediated by stimulation of IGF production in the fetus and
by increasing the availability of nutrients to fetal tissues. Se-
veral proteins like apolipoprotein A1, retinoic acid, vitamin
D3, and even thyroid hormones, are implicated in the regulation
of placental lactogen expression. Increased GH levels as those
observed in the cord blood of Group I neonates may lead to
increases in placental transport capacity, and may cause ana-
bolic effects in the mother which may result in limiting fetal
substrate supply and therefore prevent an increase in fetal
growth (30,31).
Thyroid hormones are critical to growth and development of
the human fetus. We and other investigators have documented
that malnutrition during pregnancy induces a reduction of
serum T3 and TSH , this results in reciprocal up regulation of
T4 production by the thyroid gland (31). It is speculated that
reduced synthesis of thyroid hormone (T3) and TSH in
growth retarded fetuses may be due to hypoxic suppression
of thyroid function, or a hypothyroid state with a consequent
decrease in metabolic rate and oxygen consumption, which
would be a beneficial adaptation of the fetus to the stimulus
of maternal malnutrition (10). Therefore we speculate this
beneficial adaptation may be occurring in the growth restricted
neonates. Additionally, increased levels of prolactin are often
observed in hypothyroidism resulting from low iodine intake,
therefore the increased prolactin levels in the cord blood of
the Group I neonates may be a consequence of thyroid hor-
mone dysregulation that occurs due to maternal nutritional
restriction. Placental restriction of fetal growth is known to
increase circulating thyroid hormone concentrations and
particularly T4 activation (31).
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We believe that significantly lower levels of cord blood
insulin observed in the cord blood of Group I neonates in our
study, could alter maternal growth factor levels and that these
changes may direct the metabolic and growth adaptation of the
mother to pregnancy, which ensures an adequate flow of
substrates to the developing fetus trying to compensate a
growth disadvantage due to maternal nutritional restrictions.
Both, insulin and thyroid hormones are controlled by the supply
of glucose and oxygen, respectively, and they influence fetal
growth, partly via IGF-I (8,9). We observed decreased IGF-1
levels in both maternal and cord blood in Group I
mothers and their neonates, but no statistically significant
differences were observed between the control group and
study group. Nevertheless, since the fetus is known to
control the placental utilization of substrates via its blood con-
centrations of oxygen and glucose and possibly via IGF-I, the
levels of placental lactogen, can alter the stability and concen-
trations of IGF binding proteins and the levels of circulating
IGFs. IGF-I levels are modulated by both insulin and glucose
and IGF-I may increase blood glucose concentration or mater-
nal hyperglycemia by inhibiting insulin secretion and de-
creasing insulin concentration as observed in both cord and
maternal blood levels in neonates and mothers belonging to
Group I. Deficiencies in either fetal or maternal insulin secre-
tion during pregnancy can alter fetal growth and have important
consequences for perinatal survival and postnatal morbidity.
The endocrine modulation in Group I mothers and their neo-
nates cannot be solely attributed to the amount of weight
gained in pregnancy. Pre-pregnancy weight, nutritional status
both before and during pregnancy significantly influences fe-
tal growth and development, and all of these anthropometric
measurements are interrelated. Therefore, we did a multivariate
regression analysis (Table 5) to establish a correlation if any,
between weight gain in pregnancy and the anthropometric,
biochemical and endocrine parameters studied. Figure I
shows the significant correlations between weight gain in
pregnancy in some of the key anthropometric and endocrine
parameters. Although other studies suggest that weight gain
during pregnancy represents short-term maternal nutritional
status and accounts for only 5.6% of the variance in birth
weight (15-19), our results show that poor weight gain in
pregnancy can significantly modulate various endocrine and
anthropometric parameters. Thus, weight gain in pregnancy
is a significant factor that influences both maternal and fetal
well being, and is key to a favorable neonatal outcome.
Over the last several decades important information about
the role of nutrition in the course and outcome of pregnancy
has been assimilated (32-35). The fetus has been termed as
a “parasite”, who draws on maternal stores for support.
However, researchers believe that a limit exists as to the ability
of the fetus to drain maternal supplies. The consequences of
poor maternal nutrition range from the development of ame-
norrhea to the stimulation of spontaneous abortion, stillbirth
and congenital malformations. Limited maternal weight gain
and subsequent low birth weight is the most common result
of suboptimal maternal nutrition. Our study showed that the
incidence of poor maternal weight gain as a result of subop-
timal maternal nutrition in the population studied is 37.3%,
which is an alarmingly large number of cases comprising
almost 1/3rd of the subjects studied. The endocrine profile in
such a data set is extremely valuable information that may
lead to a better understanding of maternal-fetal physiology
and about how environmental factors such as maternal
malnutrition can adversely affect fetal development and the
neonatal and long-term outcome. In the light of “Barker’s
hypothesis”, which suggests that alterations in the maternal
endocrine, nutritional, and metabolic environment disrupt
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Multivariate regression analysis
Relationship between weight gain vs F-Statistic p value
Maternal pre-pregnancy weight 15.87 <0.0001*
Maternal weight at delivery 211.90 <0.0001*
Neonatal birth weight 263.85 <0.0001*
Ponderal Index 114.74 <0.0001*
Neonatal length 21.90 <0.0001*
Placental weight 53.58 <0.0001*
Birth weight percentile 260.48 <0.0001*
Maternal abdominal circumference 32.73 <0.0001*
Maternal mid-arm circumference 32.57 <0.0001*
Fundal height 12.94 0.0004*
Maternal hemoglobin 0.68 0.41
Cord T4 5.69 0.017*
Maternal T4 1.76 0.185
Cord T3 9.55 0.002*
Maternal T3 0.89 0.34
Cord rT3 0.91 0.34
Maternal rT3 0.47 0.49
Cord TSH 0.21 0.61
Maternal TSH 1.95 0.09
Cord growth hormone 6.19 0.013*
Maternal growth hormone 2.11 0.14
Cord prolactin 2.50 0.11
Maternal prolactin 1.79 0.18
Cord placental lactogen 4.71 0.030*
Maternal placental lactogen 0.00 0.94
Cord insulin 2.42 0.12
Maternal insulin 6.00 0.015*
Cord total protein 0.13 0.71
Maternal total protein 3.15 0.07
Cord IGF-I 0.22 0.32
Maternal IGF-I 0.74 0.43
Cord EGF 0.69 0.88
Maternal EGF 0.74 0.43
Cord albumin 1.27 0.26
Maternal albumin 3.76 0.05*
Cord ferritin 0.04 0.84
Maternal ferritin 1.61 0.20
* denotes statistically significant differences between the dependent
and independent variables. F-statics: ratio of mean square/error
variance.
Table 5. Multivariate regression analyses between weight gain
during pregnancy and maternal-fetal anthropometric, biochemical
and endocrine parameters
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the developmental trajectory of the fetus, and can lead to
adult diseases, more research studies such as ours needs to
be done to evaluate the complex relationship between ma-
ternal nutritional status, fetal growth retardation, postnatal
catch-up growth, and early markers of future adult diseases.
Monthly monitoring of weight gain in pregnancy may not be
feasible for many developing country settings, but a mini-
mum of two measurements can be taken at least one month
apart anytime during the second or third trimester. Lack of
weight gain of approximately 1 kg per month or weight loss
between two consecutive measurements is very detrimental
to the fetus and/or mother and requires immediate action.
Where weight-gain monitoring is not feasible at all,
screening with measurements that require only one contact
with a woman, such as prepregnancy weight (or weight-for-
height or arm circumference) is still predictive of pregnancy
outcome (16,18,27,31). There is an urgent need for research
to assist in the development of pregnancy weight-gain charts
which establish appropriate weight-gain curves for women
in developing countries. These charts should be clear about
the outcomes they are intended to predict and prevent, such
as LBW or mortality. Improving pre-pregnancy weight and
weight gain during pregnancy are effective strategies which
reduce and prevent LBW and adequate nutritional
supplementation will result in LBW neonates to experience
catch-up growth and achieve normal postnatal growth.
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Figure 1 [A-L]: Graphical representation of multiple regression analysis between weight gain during pregnancy confirming an unbiased rela-
tionship between these parameters.
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